SequelSEC

enVVeno Medical Corp NVNO

Surgical & Medical Instruments & Apparatus · CIK 0001661053 · Fiscal year ends 1231

Revenue
$31.24K
Fiscal year ended 2019-12-31
Operating income
-$7.68M
Fiscal year ended 2019-12-31
Free cash flow
-$6.26M
Fiscal year ended 2019-12-31

Valuation, from the filing

Public float$76.10MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$116.09Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today.

How this compares in its industry

Percentile among the Surgical & Medical Instruments & Apparatus filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
CapEx / revenue1164.7%100th
FCF margin-20037.4%0th
Net margin-24406.7%0th
Operating margin-24566.5%1th
R&D / revenue7061.2%99th
SBC / revenue3015.0%98th
Revenue YoY growth-83.3%4th
Current ratio0.76x13th

enVVeno Medical Corp (NVNO) reported revenue of $31.24K and net income of -$7.63M for the fiscal year ended 2019-12-31. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from enVVeno Medical Corp’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

enVVeno Medical Corp income by fiscal year, in US dollars, normalized from SEC filings.
Metric2019-12-31
Revenue$31.24K
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$7.68M
Net income-$7.63M
Research & development$2.21M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrative$4.91M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

enVVeno Medical Corp balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2019-12-31
Cash & equivalents$1.31M
Total assets$3.43M
Current assets$1.42M
Total liabilities$2.44M
Current liabilities$1.88M
Total equity incl. NCI$989.94K
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$1.22M

Cash flow

enVVeno Medical Corp cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2019-12-31
Operating cash flow-$5.90M
Capital expenditures$363.89K
Investing cash flow-$363.89K
Financing cash flow$5.64M
Net change in cash-$623.36K
Stock-based compensation$941.96K
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$123.66K

Derived

enVVeno Medical Corp derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2019-12-31
Free cash flow-$6.26M
Gross marginUnavailable
Operating margin-24566.5%
FCF margin-20037.4%
SBC / revenue3015.0%
Current ratio0.76x
Revenue YoY growth-83.3%
Net margin-24406.7%
R&D / revenue7061.2%
CapEx / revenue1164.7%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open NVNO in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-10-29View SEC filing
10-Q · Filed 2026-07-30View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-K · Filed 2026-03-26View SEC filing
10-Q · Filed 2025-10-30View SEC filing
10-Q · Filed 2025-07-31View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.